![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Dexilant-Generic (dexlansoprazole) is a proton pump inhibitor (PPI) indicated for healing of all grades of erosive esophagitis (EE), maintaining healing of EE and relief of heartburn & treating heartburn associated with symptomatic non-erosive GERD.
Lead Product(s): Dexlansoprazole
Therapeutic Area: Gastroenterology Product Name: Dexilant-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024